These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 35288393)

  • 1. AKATSUKI study: a prospective, multicentre, phase IV study evaluating the safety of emicizumab under and immediately after immune tolerance induction therapy in persons with congenital haemophilia A with factor VIII inhibitors.
    Matsushita T; Suzuki N; Nagao A; Nagae C; Yamaguchi-Suita H; Kyogoku Y; Ioka A; Nogami K
    BMJ Open; 2022 Mar; 12(3):e057018. PubMed ID: 35288393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study.
    Pipe SW; Shima M; Lehle M; Shapiro A; Chebon S; Fukutake K; Key NS; Portron A; Schmitt C; Podolak-Dawidziak M; Selak Bienz N; Hermans C; Campinha-Bacote A; Kiialainen A; Peerlinck K; Levy GG; Jiménez-Yuste V
    Lancet Haematol; 2019 Jun; 6(6):e295-e305. PubMed ID: 31003963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AOZORA: long-term safety and joint health in paediatric persons with haemophilia A without factor VIII inhibitors receiving emicizumab - protocol for a multicentre, open-label, phase IV clinical study.
    Shima M; Takedani H; Kitsukawa K; Taki M; Ishiguro A; Nagao A; Yamaguchi-Suita H; Kyogoku Y; Yoshida S; Nogami K
    BMJ Open; 2022 Jun; 12(6):e059667. PubMed ID: 35697445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Key questions in the new hemophilia era: update on concomitant use of FVIII and emicizumab in hemophilia A patients with inhibitors.
    Carcao M; Mancuso ME; Young G; Jiménez-Yuste V
    Expert Rev Hematol; 2021 Feb; 14(2):143-148. PubMed ID: 33499681
    [No Abstract]   [Full Text] [Related]  

  • 5. Immune tolerance induction in paediatric patients with haemophilia A and inhibitors receiving emicizumab prophylaxis.
    Batsuli G; Zimowski KL; Tickle K; Meeks SL; Sidonio RF
    Haemophilia; 2019 Sep; 25(5):789-796. PubMed ID: 31373431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab.
    Carcao M; Escuriola-Ettingshausen C; Santagostino E; Oldenburg J; Liesner R; Nolan B; Bátorová A; Haya S; Young G;
    Haemophilia; 2019 Jul; 25(4):676-684. PubMed ID: 31033112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study.
    Négrier C; Mahlangu J; Lehle M; Chowdary P; Catalani O; Bernardi RJ; Jiménez-Yuste V; Beckermann BM; Schmitt C; Ventriglia G; Windyga J; d'Oiron R; Moorehead P; Koparkar S; Teodoro V; Shapiro AD; Oldenburg J; Hermans C
    Lancet Haematol; 2023 Mar; 10(3):e168-e177. PubMed ID: 36716761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors.
    Shima M; Nogami K; Nagami S; Yoshida S; Yoneyama K; Ishiguro A; Suzuki T; Taki M
    Haemophilia; 2019 Nov; 25(6):979-987. PubMed ID: 31515851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose immune tolerance induction therapy in children of Arab descent with severe haemophilia A, high inhibitor titres and poor prognostic factors for immune tolerance induction treatment success.
    Elalfy M; Elghamry I; Hassab H; Elalfy O; Andrawes N; El-Ekiaby M
    Haemophilia; 2022 Jan; 28(1):65-72. PubMed ID: 34797008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study.
    Kreuz W; Escuriola Ettingshausen C; Vdovin V; Zozulya N; Plyushch O; Svirin P; Andreeva T; Bubanská E; Campos M; Benedik-Dolničar M; Jiménez-Yuste V; Kitanovski L; Klukowska A; Momot A; Osmulskaya N; Prieto M; Šalek SZ; Velasco F; Pavlova A; Oldenburg J; Knaub S; Jansen M; Belyanskaya L; Walter O; ;
    Haemophilia; 2016 Jan; 22(1):87-95. PubMed ID: 26202305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune tolerance induction in the era of emicizumab - still the first choice for patients with haemophilia A and inhibitors?
    Holstein K; Le Quellec S; Klamroth R; Batorova A; Holme PA; Jiménez-Yuste V; Astermark J
    Haemophilia; 2022 Mar; 28(2):215-222. PubMed ID: 34918839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study protocol for assessment of the coagulation potential of concomitantly used factor VIII concentrates in patients with haemophilia A with emicizumab prophylaxis (CAGUYAMA Study): a multicentre open-label non-randomised clinical trial.
    Takeyama M; Ozu N; Kasama S; Kasahara M; Matsumoto M; Shima M; Nogami K
    BMJ Open; 2023 Jul; 13(7):e072565. PubMed ID: 37429679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors.
    Mahlangu J; Oldenburg J; Paz-Priel I; Negrier C; Niggli M; Mancuso ME; Schmitt C; Jiménez-Yuste V; Kempton C; Dhalluin C; Callaghan MU; Bujan W; Shima M; Adamkewicz JI; Asikanius E; Levy GG; Kruse-Jarres R
    N Engl J Med; 2018 Aug; 379(9):811-822. PubMed ID: 30157389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of the outcome of immune tolerance induction in patients with haemophilia A and inhibitors: The Brazilian Immune Tolerance (BrazIT) Study protocol.
    Camelo RM; Chaves DG; Zuccherato LW; Rezende SM;
    PLoS One; 2021; 16(8):e0256265. PubMed ID: 34437573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of global coagulation function under treatment with emicizumab concomitantly with bypassing agents in haemophilia A with inhibitor (UNEBI Study): multicentre open-label non-randomised clinical trial.
    Ogiwara K; Taki M; Suzuki T; Takedani H; Matsushita T; Amano K; Matsumoto M; Nishio K; Shima M; Kasahara M; Nogami K
    BMJ Open; 2022 Feb; 12(2):e056922. PubMed ID: 35177463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic impact model of delayed inhibitor development in patients with hemophilia a receiving emicizumab for the prevention of bleeding events.
    Patel AM; Corman SL; Chaplin S; Raimundo K; Sidonio RF
    J Med Econ; 2019 Dec; 22(12):1328-1337. PubMed ID: 31530050
    [No Abstract]   [Full Text] [Related]  

  • 17. Predicted coagulation potential using an in vitro simulated model of emicizumab prophylaxis and immune tolerance induction therapy in hemophilia A patients with inhibitor.
    Nakajima Y; Tonegawa H; Noguchi-Sasaki M; Nogami K
    Int J Hematol; 2021 Jun; 113(6):789-796. PubMed ID: 33635530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune tolerance induction in severe haemophilia A: A UKHCDO inhibitor and paediatric working party consensus update.
    Hart DP; Alamelu J; Bhatnagar N; Biss T; Collins PW; Hall G; Hay C; Liesner R; Makris M; Mathias M; Motwani J; Palmer B; Payne J; Percy C; Richards M; Riddell A; Talks K; Tunstall O; Chalmers E
    Haemophilia; 2021 Nov; 27(6):932-937. PubMed ID: 34403546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Model of Short- and Long-Term Outcomes of Emicizumab Prophylaxis Treatment for Persons with Hemophilia A.
    Zhou ZY; Raimundo K; Patel AM; Han S; Ji Y; Fang H; Zhong J; Betts KA; Mahajerin A
    J Manag Care Spec Pharm; 2020 Sep; 26(9):1109-1120. PubMed ID: 32452276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Substitution therapy.
    Shima M; Sidonio RF
    Haemophilia; 2021 Feb; 27 Suppl 3():53-59. PubMed ID: 32558019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.